Sage Therapeutics (SAGE) Financials

$6.52 +0.04 (+0.62%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$6.49 -0.03 (-0.52%)

As of 05/29/2025 07:57 PM Eastern

Annual Income Statements for Sage Therapeutics

This table shows Sage Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-401	-541	-533
Consolidated Net Income / (Loss)	-401	-541	-533
Net Income / (Loss) Continuing Operations	-401	-541	-533
Total Pre-Tax Income	-401	-541	-533
Total Operating Income	-432	-580	-547
Total Gross Profit	41	86	7.69
Total Revenue	41	86	7.69
Operating Revenue	41	86	7.69
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	474	666	555
Selling, General & Admin Expense	216	275	228
Research & Development Expense	226	356	326
Other Operating Expenses / (Income)	9.44	2.16	0.81
Restructuring Charge	22	33	0.00
Total Other Income / (Expense), net	32	38	14
Interest & Investment Income	32	39	14
Other Income / (Expense), net	0.03	-0.38	-
Basic Earnings per Share	($6.59)	($9.05)	($8.98)
Weighted Average Basic Shares Outstanding	60.77M	59.84M	59.31M
Diluted Earnings per Share	($6.59)	($9.05)	($8.98)
Weighted Average Diluted Shares Outstanding	60.77M	59.84M	59.31M
Weighted Average Basic & Diluted Shares Outstanding	61.48M	60.11M	59.72M

This table shows Sage Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Consolidated Net Income / (Loss)	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Net Income / (Loss) Continuing Operations	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Total Pre-Tax Income	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Total Operating Income	-67	-102	-101	-111	-118	-42	-212	-170	-155	-154	-141
Total Gross Profit	14	19	6.59	8.65	6.63	78	2.72	2.27	3.06	3.53	1.56
Total Revenue	14	13	12	8.65	7.90	78	2.72	2.47	3.29	2.86	1.74
Operating Revenue	14	13	12	8.65	7.90	78	2.72	2.47	3.29	2.86	1.74
Total Cost of Revenue	0.00	-6.55	5.28	0.00	1.27	-0.44	0.00	0.21	0.23	-0.67	0.18
Total Operating Expenses	82	122	108	120	124	120	215	173	159	157	143
Selling, General & Admin Expense	58	55	53	56	53	55	78	76	66	67	61
Research & Development Expense	23	37	55	63	72	64	102	97	93	89	82
Other Operating Expenses / (Income)	0.66	-	-	1.41	-	-	0.91	-	-	-	-
Restructuring Charge	0.51	-	0.00	-	-	-	34	-	-	-	0.00
Total Other Income / (Expense), net	5.24	6.43	7.64	8.43	9.20	9.08	10	10	8.83	6.76	4.16
Interest & Investment Income	5.22	6.40	7.64	8.43	9.20	9.47	10	10	8.83	6.79	4.13
Other Income / (Expense), net	0.02	-	-	-	-	-	-	-	-	-	0.03
Basic Earnings per Share	($1.01)	($1.56)	($1.53)	($1.70)	($1.80)	($0.54)	($3.37)	($2.68)	($2.46)	($2.47)	($2.31)
Weighted Average Basic Shares Outstanding	61.86M	60.77M	61.12M	60.54M	60.14M	59.84M	59.91M	59.77M	59.67M	59.31M	59.43M
Diluted Earnings per Share	($1.01)	($1.56)	($1.53)	($1.70)	($1.80)	($0.54)	($3.37)	($2.68)	($2.46)	($2.47)	($2.31)
Weighted Average Diluted Shares Outstanding	61.86M	60.77M	61.12M	60.54M	60.14M	59.84M	59.91M	59.77M	59.67M	59.31M	59.43M
Weighted Average Basic & Diluted Shares Outstanding	62.62M	61.48M	61.17M	61.05M	60.18M	60.11M	59.97M	59.88M	59.76M	59.72M	59.49M

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	10	-92	-132
Net Cash From Operating Activities	-267	-541	-460
Net Cash From Continuing Operating Activities	-267	-541	-460
Net Income / (Loss) Continuing Operations	-401	-541	-533
Consolidated Net Income / (Loss)	-401	-541	-533
Depreciation Expense	1.03	1.39	1.12
Amortization Expense	-6.48	-6.34	5.85
Non-Cash Adjustments To Reconcile Net Income	59	79	66
Changes in Operating Assets and Liabilities, net	79	-73	0.09
Net Cash From Investing Activities	267	443	325
Net Cash From Continuing Investing Activities	267	443	325
Purchase of Property, Plant & Equipment	0.00	-0.55	-0.94
Purchase of Investments	-451	-595	-881
Sale and/or Maturity of Investments	718	1,038	1,207
Net Cash From Financing Activities	11	6.03	3.07
Net Cash From Continuing Financing Activities	11	6.03	3.07
Repurchase of Common Equity	-0.12	0.00	0.00
Issuance of Common Equity	11	6.93	3.11
Other Financing Activities, net	-0.40	-0.90	-0.04

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-36	-20	-0.27	-73	103	-78	27	-85	44	-37	-6.68
Net Cash From Operating Activities	-82	-67	-82	-80	-38	-120	-136	-132	-154	-127	-119
Net Cash From Continuing Operating Activities	-82	-67	-82	-80	-38	-120	-136	-132	-154	-127	-119
Net Income / (Loss) Continuing Operations	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Consolidated Net Income / (Loss)	-62	-96	-94	-103	-108	-33	-202	-160	-147	-147	-137
Depreciation Expense	0.11	0.13	0.26	0.31	0.34	0.41	0.33	0.33	0.32	0.29	0.28
Amortization Expense	-0.98	-0.94	-2.05	-1.94	-1.55	6.18	-4.95	-4.39	-3.18	-1.33	1.07
Non-Cash Adjustments To Reconcile Net Income	7.19	9.90	16	19	15	14	30	13	21	17	15
Changes in Operating Assets and Liabilities, net	-26	20	-2.62	5.35	57	-108	40	20	-25	4.61	2.54
Net Cash From Investing Activities	46	47	81	-0.39	139	42	160	46	195	90	111
Net Cash From Continuing Investing Activities	46	47	81	-0.39	139	42	160	46	195	90	111
Purchase of Property, Plant & Equipment	0.00	-	-	-	0.00	0.11	-0.33	-0.11	-0.23	-0.28	-0.36
Purchase of Investments	-88	-89	-102	-198	-62	-135	-70	-233	-157	-199	-251
Sale and/or Maturity of Investments	134	135	183	198	201	177	231	278	352	289	363
Net Cash From Financing Activities	0.15	-0.00	1.04	8.07	1.56	-0.26	2.77	0.85	2.67	0.03	1.23
Net Cash From Continuing Financing Activities	0.15	-0.00	1.04	8.07	1.56	-0.26	2.77	0.85	2.67	0.03	1.23
Repurchase of Common Equity	0.00	-	-	-	-	-	-	-	-	-	-
Issuance of Common Equity	0.24	-0.00	1.44	8.19	1.56	-	2.77	0.86	3.30	0.03	1.24
Other Financing Activities, net	-0.09	-0.00	-0.40	-0.00	-0.00	-0.26	-0.00	-0.01	-0.63	-0.00	-0.02

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	547	882	1,356
Total Current Assets	531	869	1,337
Cash & Equivalents	81	71	163
Restricted Cash	0.00	1.33	0.00
Short-Term Investments	423	682	1,110
Accounts Receivable	9.13	83	14
Prepaid Expenses	18	32	51
Plant, Property, & Equipment, net	0.89	1.92	2.90
Total Noncurrent Assets	15	11	17
Other Noncurrent Operating Assets	14	11	15
Other Noncurrent Nonoperating Assets	1.45	0.00	1.27
Total Liabilities & Shareholders' Equity	547	882	1,356
Total Liabilities	82	83	104
Total Current Liabilities	72	83	99
Accounts Payable	13	10	19
Accrued Expenses	58	67	73
Other Current Liabilities	1.32	5.17	7.64
Total Noncurrent Liabilities	11	0.00	4.59
Other Noncurrent Operating Liabilities	11	0.00	4.59
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	465	800	1,253
Total Preferred & Common Equity	465	800	1,253
Preferred Stock	0.00	0.00	0.00
Total Common Equity	465	800	1,253
Common Stock	3,436	3,370	3,291
Retained Earnings	-2,970	-2,570	-2,028
Treasury Stock	-0.40	-0.40	-0.40
Accumulated Other Comprehensive Income / (Loss)	0.24	-0.81	-10

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	470	622	697	768	950	1,082	1,221	1,486
Total Current Assets	454	605	687	755	933	1,064	1,203	1,465
Cash & Equivalents	45	100	100	173	149	121	207	200
Short-Term Investments	379	470	547	544	727	881	923	1,194
Accounts Receivable	11	15	9.94	11	23	15	15	18
Prepaid Expenses	20	20	29	27	35	46	59	53
Plant, Property, & Equipment, net	0.78	1.02	1.27	1.59	2.44	2.48	2.66	2.82
Total Noncurrent Assets	14	16	9.02	11	14	16	15	18
Other Noncurrent Operating Assets	13	16	9.02	9.07	13	14	13	17
Other Noncurrent Nonoperating Assets	1.45	0.00	0.00	1.50	1.33	1.33	1.27	1.27
Total Liabilities & Shareholders' Equity	470	622	697	768	950	1,082	1,221	1,486
Total Liabilities	60	71	69	62	133	98	88	106
Total Current Liabilities	50	60	69	62	133	97	85	100
Accounts Payable	5.44	7.13	8.65	6.48	11	9.28	12	7.08
Accrued Expenses	43	53	59	52	115	80	65	85
Other Current Liabilities	1.81	0.08	1.41	3.31	6.97	7.73	7.68	7.60
Total Noncurrent Liabilities	10	10	0.00	0.00	0.00	1.11	2.87	6.26
Other Noncurrent Operating Liabilities	10	10	-	-	0.00	1.11	2.87	6.26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	410	552	628	706	817	984	1,133	1,380
Total Preferred & Common Equity	410	552	628	706	817	984	1,133	1,380
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	410	552	628	706	817	984	1,133	1,380
Common Stock	3,443	3,426	3,410	3,385	3,358	3,326	3,314	3,276
Retained Earnings	-3,033	-2,875	-2,781	-2,678	-2,537	-2,335	-2,175	-1,881
Treasury Stock	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40
Accumulated Other Comprehensive Income / (Loss)	0.14	0.90	-0.69	-0.79	-3.74	-5.64	-5.09	-15

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-52.30%	1,024.84%	21.85%
EBITDA Growth	25.19%	-8.36%	-21.71%
EBIT Growth	25.49%	-6.08%	-18.68%
NOPAT Growth	25.43%	-6.01%	-18.68%
Net Income Growth	26.01%	-1.63%	-16.36%
EPS Growth	27.18%	-0.78%	-15.13%
Operating Cash Flow Growth	50.57%	-17.51%	-21.64%
Free Cash Flow Firm Growth	54.06%	-25.46%	-11.64%
Invested Capital Growth	-190.59%	312.69%	-45.62%
Revenue Q/Q Growth	-61.24%	661.85%	18.90%
EBITDA Q/Q Growth	-18.23%	16.91%	-6.74%
EBIT Q/Q Growth	-16.14%	16.11%	-5.48%
NOPAT Q/Q Growth	-16.15%	16.17%	-5.48%
Net Income Q/Q Growth	-18.68%	17.45%	-4.40%
EPS Q/Q Growth	-18.31%	17.58%	-4.06%
Operating Cash Flow Q/Q Growth	16.54%	1.35%	-6.83%
Free Cash Flow Firm Q/Q Growth	28.34%	-7.72%	-5.40%
Invested Capital Q/Q Growth	-118.64%	174.13%	-43.14%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,061.49%	-676.86%	-7,025.94%
Operating Margin	-1,048.35%	-670.69%	-7,116.69%
EBIT Margin	-1,048.28%	-671.14%	-7,116.69%
Profit (Net Income) Margin	-971.48%	-626.32%	-6,931.88%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	92.67%	93.32%	97.41%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-14,293.22%	-3,403.73%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-14,277.67%	-3,390.36%	0.00%
Return on Net Nonoperating Assets (RNNOA)	14,229.86%	3,350.95%	0.00%
Return on Equity (ROE)	-63.37%	-52.77%	-35.74%
Cash Return on Invested Capital (CROIC)	0.00%	-1,048.72%	0.00%
Operating Return on Assets (OROA)	-60.49%	-51.84%	-34.38%
Return on Assets (ROA)	-56.06%	-48.37%	-33.49%
Return on Common Equity (ROCE)	-63.37%	-52.77%	-35.74%
Return on Equity Simple (ROE_SIMPLE)	-86.15%	-67.73%	-42.53%
Net Operating Profit after Tax (NOPAT)	-303	-406	-383
NOPAT Margin	-733.84%	-469.49%	-4,981.68%
Net Nonoperating Expense Percent (NNEP)	-15.55%	-13.37%	-9.94%
Return On Investment Capital (ROIC_SIMPLE)	-65.08%	-50.77%	-30.57%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	524.74%	317.53%	2,962.52%
R&D to Revenue	547.72%	412.05%	4,243.60%
Operating Expenses to Revenue	1,148.35%	770.69%	7,216.69%
Earnings before Interest and Taxes (EBIT)	-432	-580	-547
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-438	-585	-540
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.71	1.63	1.81
Price to Tangible Book Value (P/TBV)	0.71	1.63	1.81
Price to Revenue (P/Rev)	8.05	15.03	295.22
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	12.11	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	6.30	129.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.00	-0.99	-1.01
Leverage Ratio	1.13	1.09	1.07
Compound Leverage Factor	1.05	1.02	1.04
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-6.70	4.34	10.79
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.42	10.51	13.47
Quick Ratio	7.17	10.11	12.96
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-217	-472	-376
Operating Cash Flow to CapEx	0.00%	-97,754.97%	-49,096.69%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.06	0.08	0.00
Accounts Receivable Turnover	0.90	1.79	0.48
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	29.34	35.88	2.60
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	407.73	204.06	763.76
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	407.73	204.06	763.76
Capital & Investment Metrics	-	-	-
Invested Capital	-41	45	-21
Invested Capital Turnover	19.48	7.25	-0.43
Increase / (Decrease) in Invested Capital	-86	66	-6.63
Enterprise Value (EV)	-172	545	997
Market Capitalization	332	1,299	2,269
Book Value per Share	$7.60	$13.33	$21.05
Tangible Book Value per Share	$7.60	$13.33	$21.05
Total Capital	465	800	1,253
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-504	-755	-1,272
Capital Expenditures (CapEx)	0.00	0.55	0.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-45	32	-35
Debt-free Net Working Capital (DFNWC)	460	787	1,238
Net Working Capital (NWC)	460	787	1,238
Net Nonoperating Expense (NNE)	98	136	150
Net Nonoperating Obligations (NNO)	-506	-755	-1,274
Total Depreciation and Amortization (D&A)	-5.45	-4.95	6.98
Debt-free, Cash-free Net Working Capital to Revenue	-108.46%	37.11%	-452.42%
Debt-free Net Working Capital to Revenue	1,114.58%	909.84%	16,103.58%
Net Working Capital to Revenue	1,114.58%	909.84%	16,103.58%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($6.59)	($9.05)	($8.98)
Adjusted Weighted Average Basic Shares Outstanding	60.77M	59.84M	59.31M
Adjusted Diluted Earnings per Share	($6.59)	($9.05)	($8.98)
Adjusted Weighted Average Diluted Shares Outstanding	60.77M	59.84M	59.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.48M	60.11M	59.72M
Normalized Net Operating Profit after Tax (NOPAT)	-287	-383	-383
Normalized NOPAT Margin	-696.75%	-442.45%	-4,981.68%
Pre Tax Income Margin	-971.48%	-626.32%	-6,932.07%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.03%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.97%	-83.56%	337.08%	249.80%	139.89%	2,622.45%	56.18%	64.82%	108.22%	74.42%	20.76%
EBITDA Growth	42.55%	-190.30%	52.42%	35.29%	24.91%	77.10%	-54.51%	-39.01%	-32.61%	-28.23%	-10.77%
EBIT Growth	42.69%	-142.89%	52.23%	34.70%	24.31%	72.66%	-49.77%	-32.75%	-26.19%	-22.64%	-8.06%
NOPAT Growth	42.68%	-142.89%	52.23%	34.70%	24.31%	72.66%	-49.74%	-32.75%	-26.19%	-22.64%	-8.09%
Net Income Growth	42.65%	-192.85%	53.60%	35.85%	26.12%	77.77%	-46.83%	-26.98%	-20.30%	-17.99%	-5.49%
EPS Growth	43.89%	-188.89%	54.60%	36.57%	26.83%	78.14%	-45.89%	-25.82%	-18.84%	-16.51%	-4.52%
Operating Cash Flow Growth	-116.03%	44.31%	39.38%	38.84%	75.38%	5.84%	-14.30%	-23.56%	-42.56%	-30.19%	-72.70%
Free Cash Flow Firm Growth	30.65%	114.91%	-10.32%	24.61%	44.55%	5.41%	-10.02%	-46.66%	-48.44%	1.11%	3.26%
Invested Capital Growth	-10.05%	-190.59%	69.29%	-2.51%	-717.32%	312.69%	-310.69%	-565.71%	128.41%	-45.62%	-68.33%
Revenue Q/Q Growth	9.73%	7.96%	37.17%	9.52%	-89.87%	2,770.80%	9.78%	-24.89%	15.01%	64.69%	15.86%
EBITDA Q/Q Growth	33.69%	-0.01%	8.80%	5.02%	-235.07%	83.61%	-24.04%	-10.23%	-2.18%	-10.59%	-11.59%
EBIT Q/Q Growth	34.01%	-0.98%	9.07%	5.42%	-179.69%	80.14%	-24.28%	-9.64%	-1.02%	-8.80%	-10.16%
NOPAT Q/Q Growth	33.99%	-0.98%	9.07%	5.42%	-179.69%	80.14%	-24.28%	-9.64%	-1.02%	-8.78%	-10.18%
Net Income Q/Q Growth	35.04%	-2.38%	9.04%	5.19%	-231.69%	83.78%	-25.76%	-9.19%	0.22%	-7.15%	-8.76%
EPS Q/Q Growth	35.26%	-1.96%	10.00%	5.56%	-233.33%	83.98%	-25.75%	-8.94%	0.40%	-6.93%	-8.45%
Operating Cash Flow Q/Q Growth	-22.79%	19.19%	-2.40%	-112.62%	68.35%	12.03%	-3.31%	14.42%	-21.07%	-6.79%	-11.67%
Free Cash Flow Firm Q/Q Growth	-421.27%	112.63%	-45.85%	-17.21%	30.93%	6.57%	0.32%	13.79%	-17.81%	-8.67%	-32.87%
Invested Capital Q/Q Growth	62.10%	-118.64%	7.04%	-42.86%	-131.20%	174.13%	-210.26%	-960.31%	110.75%	-43.14%	-402.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	151.08%	55.54%	100.00%	83.94%	100.56%	100.00%	91.71%	93.02%	123.39%	89.42%
EBITDA Margin	-485.71%	-803.74%	-867.61%	-1,304.90%	-1,504.59%	-45.51%	-7,970.18%	-7,054.04%	-4,806.50%	-5,409.99%	-8,056.58%
Operating Margin	-479.66%	-797.39%	-852.51%	-1,286.11%	-1,489.18%	-53.96%	-7,800.04%	-6,889.94%	-4,719.79%	-5,373.71%	-8,135.71%
EBIT Margin	-479.53%	-797.39%	-852.51%	-1,286.11%	-1,489.18%	-53.96%	-7,800.04%	-6,889.94%	-4,719.79%	-5,373.71%	-8,133.99%
Profit (Net Income) Margin	-442.39%	-747.33%	-788.06%	-1,188.51%	-1,372.86%	-41.95%	-7,423.79%	-6,480.40%	-4,457.44%	-5,137.78%	-7,896.66%
Tax Burden Percent	100.00%	100.01%	99.99%	99.99%	100.01%	99.14%	100.03%	100.03%	100.13%	100.00%	100.00%
Interest Burden Percent	92.26%	93.71%	92.45%	92.43%	92.18%	78.41%	95.15%	94.03%	94.32%	95.61%	97.08%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-10,871.60%	0.00%	0.00%	0.00%	-273.84%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-10,867.75%	0.00%	0.00%	0.00%	-273.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	10,831.36%	0.00%	0.00%	0.00%	270.34%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-63.53%	-40.24%	-49.34%	-55.28%	-54.72%	-3.50%	-59.72%	-47.55%	-40.53%	-35.74%	-31.74%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,048.72%	0.00%	0.00%	-18,275.38%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.75%	-46.01%	-115.39%	-140.57%	-136.41%	-4.17%	-72.68%	-53.25%	-30.31%	-25.96%	-30.81%
Return on Assets (ROA)	-33.90%	-43.12%	-106.67%	-129.90%	-125.75%	-3.24%	-69.17%	-50.09%	-28.63%	-24.82%	-29.91%
Return on Common Equity (ROCE)	-63.53%	-40.24%	-49.34%	-55.28%	-54.72%	-3.50%	-59.72%	-47.55%	-40.53%	-35.74%	-31.74%
Return on Equity Simple (ROE_SIMPLE)	-86.47%	0.00%	-61.18%	-70.96%	-71.29%	0.00%	-80.32%	-60.10%	-49.21%	0.00%	-36.98%
Net Operating Profit after Tax (NOPAT)	-47	-72	-71	-78	-82	-29	-148	-119	-109	-108	-99
NOPAT Margin	-335.76%	-558.17%	-596.76%	-900.28%	-1,042.43%	-37.77%	-5,460.03%	-4,822.95%	-3,303.86%	-3,761.60%	-5,695.00%
Net Nonoperating Expense Percent (NNEP)	-2.62%	-3.85%	-3.14%	-3.02%	-2.82%	-0.32%	-4.69%	-3.27%	-2.76%	-2.61%	-2.36%
Return On Investment Capital (ROIC_SIMPLE)	-11.52%	-15.38%	-	-	-	-3.68%	-	-	-	-8.60%	-
Cost of Revenue to Revenue	0.00%	-51.08%	44.46%	0.00%	16.06%	-0.56%	0.00%	8.29%	6.98%	-23.39%	10.58%
SG&A Expenses to Revenue	409.52%	426.37%	448.31%	646.90%	665.33%	70.68%	2,877.10%	3,054.37%	1,994.78%	2,350.87%	3,535.48%
R&D to Revenue	161.84%	288.87%	459.74%	722.95%	907.80%	82.50%	3,752.54%	3,927.28%	2,818.03%	3,117.84%	4,689.65%
Operating Expenses to Revenue	579.66%	948.47%	908.05%	1,386.11%	1,573.12%	154.52%	7,900.04%	6,981.65%	4,812.81%	5,497.10%	8,225.13%
Earnings before Interest and Taxes (EBIT)	-67	-102	-101	-111	-118	-42	-212	-170	-155	-154	-141
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-68	-103	-103	-113	-119	-35	-216	-175	-158	-155	-140
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.19	0.71	0.80	1.04	1.59	1.63	1.51	2.85	2.21	1.81	1.69
Price to Tangible Book Value (P/TBV)	1.19	0.71	0.80	1.04	1.59	1.63	1.51	2.85	2.21	1.81	1.69
Price to Revenue (P/Rev)	10.31	8.05	4.14	6.72	12.34	15.03	108.60	270.95	266.63	295.22	359.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	12.11	0.00	0.00	604.91	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.37	0.00	0.00	0.06	4.45	6.30	31.40	174.27	146.43	129.66	144.39
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.00	-1.06	-1.02	-1.01	-0.99	-1.03	-1.01	-1.00	-1.01	-1.01
Leverage Ratio	1.11	1.13	1.15	1.10	1.08	1.09	1.11	1.08	1.06	1.07	1.06
Compound Leverage Factor	1.02	1.06	1.06	1.02	1.00	0.86	1.06	1.01	1.00	1.02	1.03
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-3.48	-4.71	-2.04	0.77	6.72	6.36	2.11	14.76	15.36	11.74	12.20
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.13	7.42	10.02	9.95	12.22	10.51	7.02	10.99	14.21	13.47	14.70
Quick Ratio	8.73	7.17	9.67	9.51	11.77	10.11	6.76	10.51	13.51	12.96	14.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-46	14	-113	-77	-66	-96	-102	-103	-119	-101	-93
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-41,422.56%	-117,426.79%	-68,303.11%	-45,011.35%	-32,655.22%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.06	0.14	0.11	0.09	0.08	0.01	0.01	0.01	0.00	0.00
Accounts Receivable Turnover	4.46	0.90	5.69	7.77	7.14	1.79	0.55	0.53	0.54	0.48	0.30
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	40.12	29.34	61.48	51.81	42.87	35.88	4.31	3.83	3.42	2.60	2.26
Accounts Payable Turnover	0.00	0.00	0.67	0.09	0.11	0.00	0.00	0.00	0.00	0.00	0.03
Days Sales Outstanding (DSO)	81.76	407.73	64.12	46.98	51.13	204.06	658.74	682.98	675.76	763.76	1,203.67
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	545.29	3,924.19	3,292.03	0.00	0.00	0.00	0.00	0.00	10,565.32
Cash Conversion Cycle (CCC)	81.76	407.73	-481.17	-3,877.21	-3,240.90	204.06	658.74	682.98	675.76	763.76	-9,361.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-15	-41	-19	-20	-14	45	-61	-20	2.28	-21	-15
Invested Capital Turnover	-3.21	19.48	-2.68	-4.91	-15.48	7.25	-0.30	-0.92	-3.28	-0.43	-0.55
Increase / (Decrease) in Invested Capital	-1.41	-86	42	-0.49	-16	66	-46	-17	10	-6.63	-6.00
Enterprise Value (EV)	65	-172	-130	5.45	405	545	356	1,807	1,376	997	933
Market Capitalization	489	332	441	654	1,124	1,299	1,232	2,810	2,506	2,269	2,327
Book Value per Share	$6.67	$7.60	$9.04	$10.44	$11.74	$13.33	$13.64	$16.47	$18.97	$21.05	$23.23
Tangible Book Value per Share	$6.67	$7.60	$9.04	$10.44	$11.74	$13.33	$13.64	$16.47	$18.97	$21.05	$23.23
Total Capital	410	465	552	628	706	800	817	984	1,133	1,253	1,380
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-424	-504	-570	-648	-718	-755	-876	-1,003	-1,130	-1,272	-1,394
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	-0.11	0.33	0.11	0.23	0.28	0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-45	-26	-30	-25	32	-76	-35	-11	-35	-28
Debt-free Net Working Capital (DFNWC)	405	460	545	618	694	787	800	967	1,119	1,238	1,365
Net Working Capital (NWC)	405	460	545	618	694	787	800	967	1,119	1,238	1,365
Net Nonoperating Expense (NNE)	15	24	23	25	26	3.25	53	41	38	39	38
Net Nonoperating Obligations (NNO)	-425	-506	-570	-648	-720	-755	-877	-1,004	-1,131	-1,274	-1,395
Total Depreciation and Amortization (D&A)	-0.87	-0.81	-1.79	-1.63	-1.22	6.59	-4.62	-4.06	-2.86	-1.04	1.35
Debt-free, Cash-free Net Working Capital to Revenue	-40.41%	-108.46%	-24.35%	-31.22%	-27.13%	37.11%	-667.84%	-341.30%	-115.34%	-452.42%	-436.60%
Debt-free Net Working Capital to Revenue	853.72%	1,114.58%	511.83%	635.28%	761.72%	909.84%	7,052.04%	9,326.20%	11,904.08%	16,103.58%	21,123.41%
Net Working Capital to Revenue	853.72%	1,114.58%	511.83%	635.28%	761.72%	909.84%	7,052.04%	9,326.20%	11,904.08%	16,103.58%	21,123.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.01)	($1.56)	($1.53)	($1.70)	($1.80)	($0.54)	($3.37)	($2.68)	($2.46)	($2.47)	($2.31)
Adjusted Weighted Average Basic Shares Outstanding	61.86M	60.77M	61.12M	60.54M	60.14M	59.84M	59.91M	59.77M	59.67M	59.31M	59.43M
Adjusted Diluted Earnings per Share	($1.01)	($1.56)	($1.53)	($1.70)	($1.80)	($0.54)	($3.37)	($2.68)	($2.46)	($2.47)	($2.31)
Adjusted Weighted Average Diluted Shares Outstanding	61.86M	60.77M	61.12M	60.54M	60.14M	59.84M	59.91M	59.77M	59.67M	59.31M	59.43M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	62.62M	61.48M	61.17M	61.05M	60.18M	60.11M	59.97M	59.88M	59.76M	59.72M	59.49M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-72	-71	-78	-82	-29	-125	-119	-109	-108	-99
Normalized NOPAT Margin	-333.21%	-558.17%	-596.76%	-900.28%	-1,042.43%	-37.77%	-4,594.07%	-4,822.95%	-3,303.86%	-3,761.60%	-5,695.00%
Pre Tax Income Margin	-442.39%	-747.24%	-788.14%	-1,188.69%	-1,372.70%	-42.31%	-7,421.76%	-6,478.74%	-4,451.73%	-5,137.57%	-7,896.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.03%	-0.03%	-0.03%	-0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Sage Therapeutics' Financials

When does Sage Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Sage Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sage Therapeutics' net income changed over the last 2 years?

Sage Therapeutics' net income appears to be on a downward trend, with a most recent value of -$400.67 million in 2024, falling from -$532.78 million in 2022. The previous period was -$541.49 million in 2023. Find out what analysts predict for Sage Therapeutics in the coming months.

What is Sage Therapeutics's operating income?

Sage Therapeutics's total operating income in 2024 was -$432.37 million, based on the following breakdown:

Total Gross Profit: $41.24 million
Total Operating Expenses: $473.61 million

How has Sage Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' total revenue changed from $7.69 million in 2022 to $41.24 million in 2024, a change of 436.6%.

How much debt does Sage Therapeutics have?

Sage Therapeutics' total liabilities were at $82.13 million at the end of 2024, a 0.7% decrease from 2023, and a 20.9% decrease since 2022.

How much cash does Sage Therapeutics have?

In the past 2 years, Sage Therapeutics' cash and equivalents has ranged from $70.99 million in 2023 to $162.70 million in 2022, and is currently $81.02 million as of their latest financial filing in 2024.

How has Sage Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' book value per share changed from 21.05 in 2022 to 7.60 in 2024, a change of -63.9%.

Related Companies

This page (NASDAQ:SAGE) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sage Therapeutics (SAGE) Financials

Frequently Asked Questions About Sage Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sage Therapeutics (SAGE) Financials

Annual Income Statements for Sage Therapeutics

Quarterly Income Statements for Sage Therapeutics

Annual Cash Flow Statements for Sage Therapeutics

Quarterly Cash Flow Statements for Sage Therapeutics

Annual Balance Sheets for Sage Therapeutics

Quarterly Balance Sheets for Sage Therapeutics

Annual Metrics And Ratios for Sage Therapeutics

Quarterly Metrics And Ratios for Sage Therapeutics

Frequently Asked Questions About Sage Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools